Sun Pharmaceutical Industries Limited has made a significant breakthrough in the treatment of severe dermatological conditions, unveiling new clinical efficacy and safety data at the 2024 European Academy of Dermatology and Venereology (EADV) Congress. The latest results, presented in Amsterdam, Netherlands, highlight the promising effects of their flagship treatment for alopecia areata, LEQSELVI (deuruxolitinib), which demonstrated substantial improvements in both hair satisfaction and mental well-being among patients.

LEQSELVI, an oral selective Janus kinase (JAK) inhibitor, has been approved by the U.S. Food and Drug Administration for the treatment of adults with severe alopecia areata. This autoimmune disease, which affects up to 2.5% of the global population, can have devastating effects, both physically and emotionally. The most striking result revealed that 95% of patients on an 8 mg twice-daily dose of LEQSELVI reported improved hair satisfaction over 24 weeks. Experts consider this a critical victory for those struggling with hair loss, which often brings profound emotional distress, such as anxiety and depression.

Expert Insight on Hair Regrowth and Mental Health

Experts in dermatology are encouraged by the breakthrough findings. Dr. Arash Mostaghimi, Vice Chair of Clinical Trials and Innovation at Brigham and Women’s Hospital, noted that the physical regrowth of hair could positively impact the emotional state of patients suffering from alopecia areata. “The data we are seeing with deuruxolitinib indicate not only physical improvement but also offer significant hope for those struggling with the mental burden of the disease,” Dr. Mostaghimi remarked. The improvements in patient-reported outcomes demonstrate the potential for LEQSELVI to transform the treatment landscape for this disease.

Boost in Mental Health: A Game Changer

In addition to improving hair satisfaction, the data presented also revealed clinically significant improvements in anxiety and depression levels. Over the 24-week study, patients reported reduced symptoms of these conditions, which are often exacerbated by alopecia areata. Given the highly visible nature of the disease, addressing both the physical and emotional aspects is considered paramount to comprehensive care.

Further studies also provided dose optimization findings. Deuruxolitinib’s 8 mg twice-daily dose outperformed higher once-daily doses, offering physicians clearer guidance on maximizing the treatment’s efficacy while minimizing side effects.

Expanding the Horizon: ILUMYA for Psoriasis

Sun Pharma also presented data for their other dermatological therapy, ILUMYA (tildrakizumab), which treats moderate-to-severe plaque psoriasis. In 12 poster presentations at the congress, the company shared insights from real-world clinical settings, confirming the therapy’s continued efficacy and safety. Research included analyses of patient well-being, productivity, and quality of life.

The company hopes that these findings will open new pathways for treating a wide range of dermatological conditions, continuing its mission to “reach people, touch lives.”

  Alopecia Areata, Brigham and Women’s Hospital, deuruxolitinib, Dr. Arash Mostaghimi, EADV Congress, European Academy of Dermatology and Venereology, FDA, ILUMYA, LEQSELVI, Plaque psoriasis, Sun Pharmaceutical Industries Limited, tildrakizumab